Beyond rituximab: the future of monoclonal antibodies in B-cell non-Hodgkin lymphoma.

Current Oncology Reports
Manzurul A Sikder, Jonathan W Friedberg

Abstract

The treatment of non-Hodgkin lymphoma (NHL) has changed dramatically since the introduction of rituximab, a monoclonal antibody that binds to the B-cell transmembrane protein CD20 and causes lysis of the lymphoma cells. Since then, a number of additional antibodies have been tested against other B-cell targets, resulting in variable efficacies. The goal of these newer agents is to achieve similar or better response rates as seen with rituximab, and perhaps demonstrate activity in rituximab-refractory disease. Several of the antibodies have been investigated in combination with each other as well as with conventional chemotherapeutic regimens. Approval of such antibodies by regulatory committees and their eventual integration into clinical practice will likely depend on positive results from randomized trials.

References

Mar 4, 1982·The New England Journal of Medicine·R A MillerR Levy
Aug 15, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P McLaughlinB K Dallaire
Feb 7, 2001·The Journal of Immunology : Official Journal of the American Association of Immunologists·E E IdusogieM G Mulkerrin
Aug 30, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·T A DavisR Levy
Oct 16, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John D HainsworthF Anthony Greco
Feb 7, 2003·Proceedings of the National Academy of Sciences of the United States of America·Sean P BohenRonald Levy
Jul 3, 2003·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardDavid M Goldenberg
Apr 23, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Rhona SteinDavid M Goldenberg
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jonathan W Friedberg
Aug 26, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John P LeonardDavid M Goldenberg
May 4, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P FeugierB Coiffier
Jun 16, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John P LeonardDavid M Goldenberg
Jun 29, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Wade T SwensonBrian K Link
Jul 5, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Myron S CzuczmanBryan R Leigh
Sep 17, 2005·Cancer Research·Che-Leung LawIqbal S Grewal
Oct 19, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard I FisherThomas P Miller
Jan 7, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·John F DiJosephNitin K Damle
Mar 4, 2006·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Mar 6, 2007·Drugs·Michelle A Fanale, Anas Younes
May 2, 2007·Annals of Oncology : Official Journal of the European Society for Medical Oncology·J P LeonardA Molina
Nov 7, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter HillmenJiri Mayer

❮ Previous
Next ❯

Citations

Jan 23, 2016·Journal of the American Academy of Dermatology·Amy HuangJacob Levitt
Mar 31, 2010·Seminars in Hematology·Roberto Stasi
Sep 25, 2016·Seminars in Oncology·Ralph E ParchmentJay A Berzofsky
Nov 4, 2010·Archives of Pathology & Laboratory Medicine·Julie Teruya-Feldstein

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.